HDAC-6 is highly overexpressed in RA patients, so it canalso be a potential target to overcome the inflammatory response.CKD-506 is a selective inhibitor of HDAC-6 and induces the acetylationof tubulin to reduce the effect of HDAC-6.175 With a precise selection of the type of HDAC, they may be utilizedas a therapeutic option for treating RA. This evidence concerns the gene HDAC9 and rheumatoid arthritis.